Frontline Nivolumab/Ipilimumab with Limited Chemo Derives OS Benefit in NSCLC

Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news